The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide sentinel-based population survey in Karnataka, India일반 인구에서 활동성 감염 및 항-SARS-CoV-2 IgG 항체의 부담: 인도 카르나타카에서 주 전역의 센티넬 기반 인구 조사 결과Article Published on 2021-07-012022-09-11 Journal: International Journal of Infectious Diseases [Category] SARS, 진단, 치료기술, [키워드] 95% CI adjusted All participant All participants anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibodies anti-SARS-CoV-2 IgG antibody Antibody testing antigen detection approach Asymptomatic Chain Reaction conducted Contact contact with COVID-19 cross-sectional survey ELISA kit estimate Fatality rate fraction geographical region geographical regions group groups healthcare facility IgG IgG antibodies India Infection Influenza Influenza-like symptoms joint Karnataka multinomial regression participant Patient platform polymerase chain reaction population immunity predictor predictors Prevalence prevalence of COVID-19 Result reverse transcription Reverse transcription-polymerase chain reaction risk RNA RT-PCR SARS-CoV-2 antigen SARS-CoV-2 IgG sensitivity sentinel Sentinel survey. stratified stratified sampling subgroup Surveillance Symptom symptomatic people threshold Variation was used [DOI] 10.1016/j.ijid.2021.05.043 PMC 바로가기 [Article Type] Article
Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers의료 종사자들 사이에서 ChAdOx1 nCoV-19 백신의 첫 번째 접종 전후의 5가지 SARS-CoV-2 항체 분석 결과 비교Immunoassays Published on 2021-06-302022-09-12 Journal: Journal of Clinical Microbiology [Category] MERS, SARS, 진단, [키워드] Abbott acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse reaction Adverse reactions All participants antibody Antibody assays Antibody titer Antibody titers applied assay assays AstraZeneca AZ vaccine baseline ChAdOx1 nCoV-19 conducted contribute coronavirus correlation correlations Cutoff Day Efficacy Factor first dose FIVE Genscript help Laboratory Participants questionnaire Result Roche SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SD Biosensor sera serum sample serum samples severe acute respiratory syndrome Coronavirus severe adverse reactions severity Siemen significantly higher single dose Spread Symptoms tested titer vaccination Vaccine Virus neutralization worker [DOI] 10.1128/JCM.01105-21 PMC 바로가기 [Article Type] Immunoassays
Prevalence and incidence of anti-SARS-CoV-2 antibodies among healthcare workers in Belgian hospitals before vaccination: a prospective cohort study예방접종 전 벨기에 병원 의료진 중 항SARS-CoV-2 항체 유병률 및 발생률: 전향적 코호트 연구Multicenter Study Published on 2021-06-292022-09-11 Journal: BMJ Open [Category] SARS, 치료기술, [키워드] 95% CI age All participants anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody Characteristics cohort study collected compatible symptoms Contact contact with COVID-19 detect effective eligible ELISA Epidemiology Euroimmun Evolution Follow-up HCW healthcare worker hospital hospitals IgG immunology incidence Infection infection control Infection prevention involved measure median age nasopharyngeal swabs neutralisation test Neutralising Antibodies neutralising antibody Nurse participant Participants Patient Physicians positive Prevalence Prevention and control Prospective prospective cohort study public health qPCR questionnaire Randomly Real-time reverse transcription PCR registration number remained reported reverse transcription PCR RT-qPCR SARS-CoV-2 selected Seroconversion seroconverted seronegative seronegative participant seropositive individuals seropositive samples Seroprevalence serum Symptom Vaccination strategy Virus neutralisation was performed was used were measured women [DOI] 10.1136/bmjopen-2021-050824 PMC 바로가기 [Article Type] Multicenter Study
COVID-19 infection among international travellers: a prospective analysis해외 여행자의 코로나19 감염: 전향적 분석Article Published on 2021-06-242022-09-11 Journal: BMJ Open [Category] SARS, 치료기술, [키워드] 95% CI All participant All participants Analysis Asymptomatic B.1.1.7 B.1.1.7 lineage Border Canada Contact Contact tracing COVID-19 COVID-19 infection COVID-19 test Critical care died enrolled estimate Follow-up Health Health policy highlight hospitalised International land limit Lineage MONITOR MOST negative test outcome participant PCR positive Positive test Prospective public health quarantine receive released required risk of COVID-19 SARS-CoV-2 B.1.1.7 secondary transmission subset Symptoms test result tested Testing [DOI] 10.1136/bmjopen-2021-050667 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trialHIV 감염에서 SARS-COV-2에 대한 Chadox1 NCOV-19 (AZD1222) 백신의 안전성 및 면역 원성 : 2/3 상 임상 시험의 단일 암 보체.Clinical Trial Published on 2021-06-182022-08-13 Journal: The Lancet. HIV [Category] MERS, SARS, 임상, 진단, [키워드] ACHE age All participants analysed analyses anti-Spike IgG anti-spike IgG response Anti-spike IgG responses antibody Antiretroviral therapy ART AstraZeneca available data AZD1222 CD4 CD4 cell CD4 count CD4 counts Cell cell-mediated immune response Cell-mediated immune responses cellular response Cellular responses ChAdOx1 ChAdOx1 nCoV-19 chill chills Clinical research clinical trial Coalition Comorbidity determined by dose Eligible participants ELISA ELISPOT enrolled enrolment enzyme enzyme-linked immunospot assay fatigue finding FIVE frequencies Frequency functional funding General population headache HIV HIV clinics HIV-negative HIV-uninfected humoral Humoral response humoral responses IFN-γ IgG response IgG responses immune responses Immunity immunogenic immunogenicity injection injection site Innovation IQR joint joint pain less Live virus Local London magnitude malaise male median median age muscle ache nausea network neutralisation NIHR NIHR Oxford Biomedical Research Centre no correlation no difference occurred Open-label outcome Oxford Pain participant Participants peaked people with HIV persistence phase 2/3 phase 2/3 trial plasma Primary outcome Primary outcomes prime-boost regimen proliferation proliferative protocol reactogenicity Registered reported required response Safe Safety SARS-CoV-2 SARS-CoV-2 spike-specific Serious Adverse Event Serious Adverse Events single-arm South sustained systemic reaction systemic reactions T-cell the vaccine undetectable vaccination Vaccine vaccine immunogenicity Valley Viral Viral load were measured with HIV [DOI] 10.1016/S2352-3018(21)00103-X PMC 바로가기 [Article Type] Clinical Trial
A blood RNA transcriptome signature for COVID-19Covid-19에 대한 혈액 RNA 전 사체 서명Research Published on 2021-06-112022-09-10 Journal: BMC Medical Genomics [Category] MERS, SARS, 유전자 메커니즘, [키워드] abnormality absence age All participants Apoptosis approach Asymptomatic Biomarkers Blood blood sample chest X-ray Chinese clinical disease clinical information Confirmed COVID-19 infection control group correlated Course COVID-19 COVID-19 infection COVID-19 patient COVID-19 patients Ct value Ct values dataset datasets determine disease disease manifestation disease pathogenesis disease severity Ethnic groups Ethnicity evaluated exposure to expression false-discovery rate feature Gender Gene Expression gene-expression greater healthy controls healthy controls; healthy volunteer immunological induced genes Influenza information magnitude median age multiple organ involvement nasal swab onset of symptom organ other respiratory infection other respiratory infections parameters participant pathway Pathways Patient presence or absence Protein qPCR respiratory respiratory infections respiratory syncytial virus respiratory viral infection response Result RNA RNA expression RNA sequencing RSV SARS-CoV-2 similarity South Asian supplementary material systemic disease the disease the patient Transcriptome unique Viral viral infection viral infections was collected Whole blood with COVID-19 [DOI] 10.1186/s12920-021-01006-w PMC 바로가기 [Article Type] Research
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study암 환자를 위한 COVID-19 백신 BNT162b2의 1회 투여 대 2회 투여의 안전성 및 면역원성: 전향적 관찰 연구의 중간 분석Observational Study Published on 2021-06-012022-09-10 Journal: The Lancet. Oncology [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] 95% CI Administered All participant All participants analysed analyses anti-S IgG antibody available data Blood blood sample Blood samples BNT162b2 BNT162b2 vaccine boost Cancer Cancer Research UK Cohort college COVID-19 COVID-19 vaccine Data analysis death dose Efficacy Efficacy and safety eight Endpoint enrolled Evidence evidence of exclusion finding first dose first vaccination FIVE Follow-up Francis Crick funding Haematological cancer Health and Care Research Wales Health Research Authority health-care healthy control healthy controls healthy controls; hospital immunogenicity immunogenicity analysis injection Injection-site pain interim analysis intramuscularly King local reaction London nasopharyngeal NHS observational study of BNT162b2 Pain participant Patient Patients with cancer patients with haematological Pfizer–BioNTech positive profile proportion prospective observational study Protein real-time RT-PCR REC receive recruited Registered reported rRT-PCR Safety SARS-CoV-2 SARS-CoV-2 spike second dose Seroconversion seropositive significantly single vaccine solid cancer Support Swab test symptomatic symptomatic COVID-19 the patient titre toxicities Toxicity Trust vaccination Vaccine Wellcome Trust [DOI] 10.1016/S1470-2045(21)00213-8 PMC 바로가기 [Article Type] Observational Study
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial60세 이상의 건강한 성인을 대상으로 한 불활성화 SARS-CoV-2 백신(CoronaVac)의 안전성, 내약성 및 면역원성: 무작위, 이중 맹검, 위약 대조, 1/2상 임상 시험Randomized Controlled Trial Published on 2021-06-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] Adults Adverse reaction Adverse reactions age All participants Aluminium aluminium hydroxide antibody Antibody Response Antibody titre assigned baseline Beijing block Block randomisation China Chinese clinical trial CoronaVac COVID-19 COVID-19 vaccine Cutoff defined detectable development dose dose-escalation double-blind eight Endpoint enrolled groups healthy hydroxide immunogenicity inactivated injection injection site pain intervention group Intramuscular injection investigators Laboratory live SARS-CoV-2 Mild moderate morbidity morbidity and mortality Neutralising Antibodies neutralising antibody neutralising antibody titres occurred Older Older adults participant Participants Phase 1 Phase 2 phase 3 trial Placebo placebo group placebo-controlled positive primary immunogenicity Program random assignment randomised Randomly receive Registered reported research and development Safe Safety safety population SARS-CoV-2 SARS-CoV-2 vaccine Science second dose Serious Adverse Events Seroconversion seroconversion rate seronegative seropositive Seven severity technology the disease the placebo group titre Tolerability treatment allocation trial protocol vaccination Vaccine virus [DOI] 10.1016/S1473-3099(20)30987-7 PMC 바로가기 [Article Type] Randomized Controlled Trial
Health Related Social Needs Among Chinese American Primary Care Patients During the COVID-19 Pandemic: Implications for Cancer Screening and Primary CareCOVID-19 팬데믹 기간 동안 중국계 미국인 1차 진료 환자의 건강 관련 사회적 요구: 암 검진 및 1차 진료에 대한 시사점Public Health Published on 2021-05-282022-09-11 Journal: Frontiers in Public Health [Category] MERS, SARS, 치료기술, [키워드] 95% CI age All participants American anticipated Asian Asian American (AA) Cancer Cancer screening Chinese cohesion Community conducted Course COVID-19 COVID-19 pandemic Critical develop effort English food insecurity Health higher odd higher odds highest highlight impacted IMPROVE initiative instability life New Older age outcome participant Participants pathway Patient patients Prevalence primary care reported resource Screening significantly social determinant social determinants social needs subset Trust upstream utility [DOI] 10.3389/fpubh.2021.674035 PMC 바로가기 [Article Type] Public Health
Seropositivity in blood donors and pregnant women during the first year of SARS‐CoV‐2 transmission in Stockholm, Sweden스웨덴 스톡홀름에서 SARS-CoV-2 전염 첫 해 동안 헌혈자와 임산부의 혈청 양성Original Article Published on 2021-05-182022-09-12 Journal: Journal of internal medicine [Category] SARS, 진단, [키워드] affecting age All participants Antibody testing approach approaches B‐cell baseline Bayesian framework blood donor Blood donors carried clinical trial clinical trials Cohort community transmission comparable competent complement Control COVID‐19 dissemination FIVE glycoprotein healthy blood donor healthy blood donors healthy donor IgG response IgG responses independent individual Infection infections information intervals Karolinska University Hospital likelihood lockdown Metadata mild infection mRNA vaccination Neutralizing antibody response neutralizing antibody responses pandemic participant Participants population immunity pregnant women Prospective Study random Randomly RBD reached receptor‐binding domain recommendations registration number Result review sampling SARS‐CoV‐2 SARS‐CoV‐2 infection SARS‐CoV‐2 spike SARS‐CoV‐2 screened second wave selected sera serology seropositive Seropositivity Seroprevalence setting study period Sweden Swedish Swedish Ethical Review Authority symptomatic tested These data titre titres trajectory Transmission trimer vaccination Vaccinations was used [DOI] 10.1111/joim.13304 PMC 바로가기 [Article Type] Original Article